Tirzepatide nume commerciale: cosa significa Mounjaro e perché conta saperlo

How the MHRA authorised tirzepatide, and why Mounjaro is the name to look for

When the MHRA grants a marketing authorisation, it licenses a specific product from a specific manufacturer. For tirzepatide, that product is Mounjaro by Eli Lilly. The international non-proprietary name (INN) (tirzepatide) exists so that clinicians worldwide can identify the active substance regardless of which country they are in. In the UK, however, you will not walk into a pharmacy and ask for "tirzepatide": you ask for Mounjaro, and your prescription will say Mounjaro.

This distinction has a practical safety dimension. The NHS medicines page for tirzepatide lists it under the scientific name for completeness, but the product information, the KwikPen label, and the Patient Information Leaflet all carry the brand name. If you come across a seller offering "tirzepatide" without mentioning Mounjaro or Eli Lilly, that is a red flag worth taking seriously.

One further note: in the United States, Eli Lilly sells tirzepatide under the brand name Zepbound for weight management. That name does not exist as a UK product. Zepbound is not licensed by the MHRA, is not stocked in UK pharmacies, and any product described as Zepbound offered for sale in the UK is not from the authorised supply chain.

What the SURMOUNT trial programme established, and how it shaped the UK licence

The clinical evidence underpinning the UK licence comes primarily from the SURMOUNT programme. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes. At the 15 mg maintenance dose over 72 weeks, average body-weight reduction reached around 20 to 21 per cent, with some analyses reporting up to approximately 22.5 per cent. Those are averages from a controlled trial population, individual results vary, and the prescriber is the right person to set expectations.

NICE reviewed this evidence in its technology appraisal TA1026, published in December 2024 and updated in September 2025, recommending tirzepatide (Mounjaro) for adults with a BMI of 35 or above plus at least one weight-related condition, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance. The key phrase in both the licence and the NICE recommendation is "alongside a reduced-calorie diet and increased physical activity": the medicine supports a broader programme, not a replacement for one.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, placed tirzepatide head-to-head against semaglutide 2.4 mg and found greater average weight loss with tirzepatide over 72 weeks. NICE's committee discussion noted that indirect comparisons also favour tirzepatide. For anyone comparing options, our page on Mounjaro versus tirzepatide terminology sets out what each name refers to and why it matters when reading clinical literature.

The UK strengths, the KwikPen, and what the titration schedule signals

Mounjaro is available in the UK in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg. Each pre-filled KwikPen contains four weekly doses. Treatment begins at 2.5 mg not because that dose drives significant weight loss, it exists to let the body adjust and to reduce the chance of early gastrointestinal side effects. Titration upward happens roughly every four weeks, guided by the prescriber based on how each person is tolerating the medicine.

Side effects across the licensed dose range are predominantly gastrointestinal: nausea, diarrhoea, constipation, indigestion, and fatigue are most commonly reported. They tend to be most noticeable in the first weeks after starting or after each dose step, then settle for most people. On safety: the MHRA's January 2026 Drug Safety Update highlighted acute pancreatitis as a known but infrequent risk across GLP-1 medicines, severe, persistent stomach pain that may radiate to the back warrants urgent medical attention. Any suspected side effect can be reported via the MHRA Yellow Card scheme.

Storage matters too. The KwikPen is refrigerated until first use; after that, a limited room-temperature window applies. The exact duration is specified in the Patient Information Leaflet, where you can also find guidance on tirzepatide l, refer there rather than relying on informal sources.

Private access to Mounjaro in the UK: what the process actually involves

The NHS is rolling out tirzepatide in phases under TA1026 criteria, starting with those who have a BMI of 40 or above and four or more qualifying conditions. That leaves a large group of people who are clinically suitable under the product licence but who do not yet meet the NHS threshold, or who would rather not wait. A private prescription through a regulated weight-loss service is the legal alternative.

Understanding the cost of Mounjaro privately is a reasonable first step, and if you are also unsure what to ask for at the pharmacy, our page on the tirzepatide commercial name explains exactly how the brand and generic names relate to one another. Eli Lilly raised UK list prices significantly from September 2025, and private market prices have shifted accordingly. The right metric for a prescription medicine is not cheapest; it is whether the supply is genuine, the clinical oversight is real, and the prescriber can be reached if something changes. If you are curious about what a properly structured private service looks like in practice, the about us page sets out how our pharmacy and prescribing team operate.

Payday orders, long weekends, or a holiday coming up can all affect how urgently people want to get started, worth knowing that orders placed before 12 pm on a working day, once clinically approved, are dispatched the same day for next-working-day delivery. When you are ready, start your free consultation to speak to our prescribers about whether Mounjaro is appropriate for you.